Zinsmeister AR. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. Am J Physiol Gastrointest Liver Physiol 292: G1359 -G1365, 2007. First published February 8, 2007 doi:10.1152/ajpgi.00403.2006.-The incretin glucagon-like peptide-1 (GLP-1), which is used to treat diabetes mellitus, delays gastric emptying by inhibiting vagal activity. GLP-1 also increases fasting and postprandial gastric volume in humans. On the basis of animal studies, we hypothesized that nitric oxide mediates the effects of GLP-1 on gastric volumes. To assess the effects of nitrergic blockade on GLP-1-induced gastric accommodation in humans, in this double-blind study, 31 healthy volunteers were randomized to placebo (i.e., saline), GLP-1, or the nitric oxidealone or with GLP-1. Thereafter, 16 additional subjects were randomized to GLP-1 alone or together with a higher dose of L-NMMA (10 mg/kg bolus plus 8 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 infusion). Gastric volumes (fasting pre-and postdrug, postprandial postdrug) were measured by 99m Tc-single-photon-emission computed tomography imaging. GLP-1 increased (P ϭ 0.04) fasting gastric volume by 83 Ϯ 16 ml (vs. 17 Ϯ 11 ml for placebo) and augmented (P Յ 0.01) postprandial accommodation by 688 Ϯ 165 ml (vs. 542 Ϯ 29 ml for placebo). L-NMMA (low dose) alone did not affect fasting or postprandial gastric volume. L-NMMA (low dose) did not attenuate the effect of GLP-1 on gastric volumes. In contrast, L-NMMA (high dose) did not affect fasting volume but blunted GLP-1-mediated postprandial accommodation (postprandial change ϭ 494 Ϯ 37 ml, P Յ 0.01 vs. GLP-1 alone). These data are consistent with the hypothesis that nitric oxide partly mediates the effects of GLP-1 on postprandial but not fasting gastric volumes in humans. accommodation; stomach; postprandial; diabetes; vagus GLUCAGON-LIKE PEPTIDE-1 (GLP-1) is an incretin produced by enteroendocrine L cells throughout the small intestine (45). The GLP-1 agonist exendin-4 improves glycemic control in patients with Type 2 diabetes mellitus inadequately treated with oral hypoglycemic agents (20). GLP-1 reduces postprandial glycemia not only by its hormonal effects (i.e., reduced glucagon and increased insulin release) (20, 29), but also by its powerful effects on gastrointestinal (GI) motility and secretion (31). Thus GLP-1 is a mediator of the ileal brake, delays gastric emptying, increases gastric volume, and reduces gastric acid secretion in humans (8,40,41). These GI effects of GLP-1 may also contribute to its side effects at pharmacological concentrations. For example, in a multicenter study of 551 patients with inadequately controlled Type 2 diabetes mellitus, 57% of patients treated with a GLP-1 agonist reported nausea and 17% reported vomiting, and GLP-1 was discontinued because of these side effects in 6% of patients (18).An intact vagus nerve is necessary for GLP-1 to delay gastric emptying in rats and pigs (21, 48) and to inhibit acid secretion in humans (49). GLP-1 also inhibits the plasma pancreatic pol...